3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Dermatologic
1
Conditions
Skin Neoplasms
1
Neoplasms
1
Carcinoma, Merkel Cell
1
Carcinoma, Basal Cell
1
Carcinoma
1
Interventions
pembrolizumab
15
Nivolumab
10
Ipilimumab
7
cemiplimab
6
dabrafenib
4
binimetinib
4
Dacarbazine
4
trametinib
3
encorafenib
3
Drug Therapy
3
Allovectin-7
3
zanolimumab
2
talabostat
2
lifileucel
2
aldesleukin
2
Vemurafenib
2
Tablets
2
Semaxinib
2
Intravital Microscopy
2
Interleukin-2
2
Fluorouracil
2
vitespin
1
veliparib
1
varlilumab
1
tozuleristide
1
tin etiopurpurin
1
tilsotolimod
1
spartalizumab
1
sotigalimab
1
sonidegib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
INDUSTRY
×
Skin Neoplasms
×
MAPRE1 protein, human
×
Clear all
NCT04349436
2026-04-22
ARTACUS
Replimune, Inc.
Phase 1/2
Active not recruiting
69 enrolled